Tiotropium

Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.

Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.

Tiotropium Bromide Inhalation (9mcg MDI, 18mcg Rotacaps) is a long-acting muscarinic antagonist (LAMA) on the WHO Model List of Essential Medicines. It binds to muscarinic M1, M2, and M3 receptors, but dissociates extremely slowly from M3 receptors (dissociation half-life ~35 hours), delivering sustained 24-hour bronchodilation from a single daily dose. Reduces lung hyperinflation, improves exercise tolerance, and significantly decreases the frequency of COPD exacerbations. Indicated for long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) and add-on maintenance in severe persistent asthma.

Tiotropium Bromide Inhalation (9mcg MDI, 18mcg Rotacaps) is a long-acting muscarinic antagonist (LAMA) on the WHO Model List of Essential Medicines. It binds to muscarinic M1, M2, and M3 receptors, but dissociates extremely slowly from M3 receptors (dissociation half-life ~35 hours), delivering sustained 24-hour bronchodilation from a single daily dose. Reduces lung hyperinflation, improves exercise tolerance, and significantly decreases the frequency of COPD exacerbations. Indicated for long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) and add-on maintenance in severe persistent asthma.

Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.